Article Sidebar
Views PDF: 70
STUDY OF rs1059513 STAT6 POLYMORPHISM IN HBsAg(+) HEPATOCELLULAR CARCINOMA PATIENTS
Main Article Content
Abstract
Objectives: To determine the genotype frequency of rs1059513 STAT6 polymorphism and its correlation with clinical, paraclinical characteristics, and cancer risk in Hepatitis B Surface Antigen positive (HBsAg (+)) hepatocellular carcinoma (HCC) patients. Methods: A cross-sectional study was conducted on 118 HBsAg-positive HCC patients, compared with 86 HBsAg-positive cirrhosis patients and 195 healthy individuals at Military Central Hospital 108, Military Hospital 103, and Can Tho City General Hospital from July 2017 to August 2020. The rs1059513 polymorphism in STAT6 was analyzed from peripheral blood samples of the study subjects using Sanger sequencing. Results: The genotype frequency of GG in the rs1059513 STAT6 polymorphism was lowest in cirrhosis patients (10.2%), but significantly higher compared to the corresponding values in HCC patients and healthy individuals (1.2% and 0%, respectively), p < 0.05. Individuals with the GG genotype had a higher risk of HBsAg-positive HCC compared to those with the AA genotype in both the cirrhosis group (OR = 11.54, 95%CI: 1.47 - 90.96, p < 0.01) and the healthy group (OR = 50.47, 95%CI: 2.95 - 863.43, p < 0.01). There was no correlation between Rs1059513 STAT6 polymorphism and age, serum AFP (Alpha fetoprotein) concentration, and some tumor characteristics. Conclusion: The GG genotype of rs1059513 STAT6 polymorphism increases the risk of HBsAg-positive HCC but is not associated with serum AFP concentration and some tumor characteristics.
Article Details
Keywords
STAT6 polymorphism., hepatocellular carcinoma
References
2. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68 (2):723-750.
3. Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular carcinoma: Molecular mechanisms and targeted therapies. Medicine. 2019; 55(9):526-547.
4. Tang JJH., Thng DKH., Lim JJ, et al. JAK/STAT signalling in hepatocellular carcinoma. Hepat Oncol. 2020; 10.2217/hep-2020-0001.
5. Dong Z, Chen Y, Yang C, et al. STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma. OncoTargets and Therapy. 2019; 12:7175-7191.
6. Lim Y, Hsu Y, Tsai K, et al. The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese. BMC Immunology. 2013; 14:21.
7. Ruan Z, Zhao Y, Yan L, et al. Single nucleotide polymorphisms in IL-4Ra, IL-13 and STAT6 genes occur in brain glioma. Frontiers in Bioscience. 2011; E3:33-45.
8. Vietnam Ministry of Health. Guidelines for diagnosis and treatment of primary liver cancer. Issued together with Decision No. 5250/QD-BYT dated December 28, 2012 by the Minister of Health (Hướng dẫn chẩn đoán và điều trị ung thư tế bào gan nguyên phát. Ban hành kèm theo Quyết định số: 5250/QĐ-BYT ngày 28 tháng 12 năm 2012 của Bộ trưởng Bộ Y tế).
9. Phan Thi Hien Luong. “Study of TNF-α-308 and TGF-β1-509 gene polymorphisms in patients with HBsAg-positive hepatocellular carcinoma” (“Nghiên cứu đa hình gen TNF-α-308 và TGF-β1-509 ở bệnh nhân ung thư biểu mô tế bào gan có HBsAg dương tính”). Doctoral thesis in Medicine. 2020. Military Medical Academy (Vietnam).
10. Duetsch G, Illig T, Loesgen S, et al. STAT6 as an asthma candidate gene: Polymorphism screening, association and haplotype analysis in a Caucasian sib-pair study. Human Molecular Genetics. 2002; 11(6):613-621.
11. Qing T, Yaminb Z, Guijie W, et al. STAT6 silencing induces hepatocellular carcinoma-derived cell apoptosis and growth inhibition by decreasing the RANKL expression. Biomedicine & Pharmacotherapy. 2017; 92:1-6.
12. Kamerkar S, Leng C, Zhang K, et al. Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC). J Immunother Cancer. 2021; 9(Suppl 2):A1-A1054.